Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers-Reference-Cited by-同舟云学术

Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers

Published:2009-03 Issue:3 Volume:10 Page:173-181
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:

Author:

Kakuda TN,Schöller-Gyüre M,De Smedt G,Beets G,Aharchi F,Peeters MP,Vandermeulen K,Woodfall BJ,Hoetelmans RMW

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1468-1293.2008.00668.x/fullpdf

Reference45 articles.

1. 1 De Corte BL. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): 15 years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 2005; 48: 1689-1696.

2. 2 Das K , Clark AD Jr. , Lewi PJ et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47: 2550-2560.

3. 3 Andries K , Azijn H , Thielemans T et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 4680-4686.

4. 4 Vingerhoets J , Azijn H , Fransen E et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79: 12773-12782.

5. 5 Gazzard BG , Pozniak AL , Rosenbaum W et al. An open-label assessment of TMC 125 - a new, next-generation NNRTI, for 7 days in HIV-1-infected individuals with NNRTI resistance. AIDS 2003; 17: F49-F54.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically-Based Pharmacokinetic Modeling of Tenofovir Disoproxil Fumarate in Pregnant Women;Current Drug Metabolism;2022-12

2. Comprehensive Study of In vivo and In vitro Metabolites of Cycloastragenol Based on UHPLC-Q-Exactive Orbitrap Mass Spectrometer;Current Drug Metabolism;2022-12

3. Case Study 7: Transporters —In Vitro Solutions for Translatable Outcomes;Methods in Molecular Biology;2021

4. A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2019-11-15

5. Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review;Clinical Pharmacokinetics;2019-11-02